Zevra Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ZVRA research report →
About the company
Zevra Therapeutics, Inc. , founded in 2006 and based in Celebration, Florida, is a biopharmaceutical company dedicated to discovering and developing innovative treatments for rare diseases. The company employs its proprietary Ligand Activated Therapy (LAT) technology to create novel prodrug versions of existing FDA-approved medications or to enable new applications for other compounds, primarily addressing serious medical conditions within the United States.
- CEO
- Neil F. McFarlane
- IPO
- 2015
- Employees
- 59
- HQ
- Celebration, FL, US
Price Chart
- Market Cap
- $826.43M
- P/E
- 6.41
- P/S
- 6.76
- P/B
- 3.97
- EV/EBITDA
- 5.21
- Div Yield
- 0.00%
- Gross Margin
- 85.51%
- Op Margin
- -39.86%
- Net Margin
- 101.58%
- ROE
- 81.34%
- ROIC
- -19.57%
- Revenue
- $106.47M · 350.91%
- Net Income
- $83.23M · 178.88%
- EPS
- $1.40 · 161.40%
- Op Income
- $-4,233,000
- FCF YoY
- 96.51%
- 52W High
- $14.58
- 52W Low
- $7.16
- 50D MA
- $11.56
- 200D MA
- $9.83
- Beta
- 0.89
- Avg Volume
- 1.57M
Get TickerSpark's AI analysis on ZVRA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 21, 26 | Thompson Rahsaan | other | 66,667 |
| Jun 22, 26 | Thompson Rahsaan | sell | 34,557 |
| Jun 21, 26 | Thompson Rahsaan | other | 66,667 |
| Jun 4, 26 | FAVORITO TAMARA A | other | 30,000 |
| Jun 4, 26 | Secor Alicia | other | 30,000 |
| Jun 4, 26 | Watton Corey Michael | other | 30,000 |
| Jun 4, 26 | Calder Douglas W | other | 30,000 |
| Jun 4, 26 | Anderson Thomas | other | 30,000 |
| Jun 4, 26 | Shih Alvin | other | 30,000 |
| May 28, 26 | Sangiovanni Timothy J. | other | 40,000 |
Our ZVRA coverage
Recent articles, reports, and earnings notes.
No research on ZVRA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ZVRA report →Similar companies
Peers in the same neighborhood.